- Home
- SNN vs GMAB Comparison
SNN vs GMAB Comparison
Compare SNN & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- GMAB
- Stock Information
- Founded
- SNN 1856
- GMAB 1999
- Country
- SNN United Kingdom
- GMAB Denmark
- Employees
- SNN N/A
- GMAB N/A
- Industry
- SNN Industrial Specialties
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SNN Health Care
- GMAB Health Care
- Exchange
- SNN Nasdaq
- GMAB Nasdaq
- Market Cap
- SNN 13.2B
- GMAB 15.4B
- IPO Year
- SNN 1999
- GMAB N/A
- Fundamental
- Price
- SNN $37.05
- GMAB $28.04
- Analyst Decision
- SNN Hold
- GMAB Buy
- Analyst Count
- SNN 3
- GMAB 6
- Target Price
- SNN $31.50
- GMAB $37.60
- AVG Volume (30 Days)
- SNN 641.0K
- GMAB 1.5M
- Earning Date
- SNN 10-30-2025
- GMAB 11-05-2025
- Dividend Yield
- SNN 1.98%
- GMAB N/A
- EPS Growth
- SNN 59.91
- GMAB 77.72
- EPS
- SNN 0.56
- GMAB 21.62
- Revenue
- SNN $5,944,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- SNN $7.75
- GMAB $24.52
- Revenue Next Year
- SNN $5.37
- GMAB $15.53
- P/E Ratio
- SNN $66.38
- GMAB $1.30
- Revenue Growth
- SNN 5.35
- GMAB 32.97
- 52 Week Low
- SNN $23.69
- GMAB $17.24
- 52 Week High
- SNN $38.79
- GMAB $28.75
- Technical
- Relative Strength Index (RSI)
- SNN 52.68
- GMAB 70.34
- Support Level
- SNN $37.10
- GMAB $27.84
- Resistance Level
- SNN $37.64
- GMAB $28.28
- Average True Range (ATR)
- SNN 0.40
- GMAB 0.38
- MACD
- SNN -0.30
- GMAB 0.00
- Stochastic Oscillator
- SNN 23.01
- GMAB 82.35
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.